Market Overview:
Point-of-care diagnostics (POC) refers to medical testing conducted directly at or near the location of patient care, instead of relying on centralized laboratories or hospital facilities. These tests are designed to provide fast and accurate results, enabling healthcare providers to make timely, informed decisions about patient diagnosis and treatment. The primary advantage of POC diagnostics is that it allows for immediate decision-making, eliminating the wait for test results and reducing the need for patients to travel to other facilities for testing.
The field of point-of-care diagnostics is experiencing rapid evolution, with significant advancements making healthcare more efficient and accessible. This trend is particularly important in Europe, where both healthcare providers and patients are increasingly adopting POC solutions to streamline the diagnostic process. With growing adoption and ongoing innovation, point-of-care diagnostics are reshaping healthcare delivery by providing quicker, more reliable results directly at the point of care.
Several key factors are driving the growth of the point-of-care diagnostics market across Europe. The rise in chronic diseases like diabetes, cardiovascular diseases, respiratory conditions, and cancer is the key driver of the POC diagnostics market. As the aging population in Europe grows, the demand for regular and convenient diagnostic tests to manage these conditions increases.
Countries like Germany, France, Italy, and the UK have seen increasing rates of cardiovascular disease, and diabetes is on the rise, leading to the adoption of POC solutions for continuous monitoring. Furthermore, Europe's aging population, along with the rising prevalence of chronic diseases, is increasing the demand for more efficient and accessible diagnostic solutions. The rising trend of home-based testing is also contributing to the shift towards point-of-care diagnostics, making it easier for patients to manage their health from the comfort of their own homes.
As innovations continue to accelerate, the market for point-of-care diagnostics in Europe is well-positioned to meet the growing needs of both healthcare providers and patients. By delivering faster, more accurate diagnostic results at the point of care, POC technology is enhancing healthcare access, improving efficiency, and ultimately leading to better patient outcomes and more effective treatment decisions.
Market Size & Growth Rate:
According to the DataM market research report, the Europe point-of-care diagnostics market size is valued at USD 3.88 billion in 2024, it is expected to reach USD 8.43 billion by 2033, with growth at a CAGR of 9.1% over the forecast period 2024-2033.
Europe Point-of-Care Diagnostics Market Segmentation
By Product
- Infectious Disease Testing Products
- Blood Glucose Products
- Blood Gas & Electrolyte Products
- Hematology Testing Products
- Urinalysis Products
- Pregnancy and Fertility Testing Products
- Tumor/Cancer Profiling Products
- Drug-of-Abuse Products
- Others
By Technology
- Lateral Flow Assays
- Immunoassays
- Molecular Diagnostics
- Microfluidics
- Others
By Application
- Infectious Diseases
- Hematology
- Cardiology
- Endocrinology
- Oncology
- Drug Testing
- Neurology
- Others
By End User
- Hospitals & Clinics
- Diagnostic Laboratories
- Home Care Settings
- Ambulatory Surgery Centers (ASCs)
By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Rest of Europe
Recent Developments in the Industry:
- In June 2023, Sysmex Corporation unveiled the world's first point-of-care (POC) testing system in Europe designed to detect antimicrobial susceptibility (the ability of bacteria to resist the effects of drugs). This system can deliver results in as little as 30 minutes.
- In July 2021, in the UK, QuantuMDx announced the launch of Q-POC, a rapid PCR-based point-of-care diagnostic system. This new product is specifically designed for front-line healthcare professionals and can be used in various clinical settings, including emergency rooms, ICUs, birthing centers, clinics, and pharmacies.
Major Companies:
Major companies involved in the Europe point-of-care diagnostics market include Abbott, F. Hoffmann-La Roche Ltd., Danaher Corporation, Siemens Healthineers AG, SEKISUI MEDICAL CO., LTD., BD, BioMérieux, QIAGEN, QuidelOrtho Corporation, and Trinity Biotech Plc, among others.
The Full Report has the following insights:
- The report offers a comprehensive evaluation of the market in terms of market value (US) and Y-o-Y Growth Rates (%). It does so via in-depth qualitative insights, historical data (2018-2033), and verifiable projections about market size during the forecast period (2024-2033).
- Visualize the composition of the Europe point-of-care diagnostics market segmentation by product, technology, application, end-user, and region, highlighting the key commercial assets and players.
- Identify commercial opportunities in the Europe point-of-care diagnostics market by analyzing trends and co-development deals.
- The report also covers data insights on various industry forces such as Porter's five forces analysis, supply chain analysis, pricing analysis, and regulatory analysis.
- Excel data sheet with thousands of data points of the Europe point-of-care diagnostics market -level 4/5 segmentation.
- PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
- Product mapping in Excel for the key product of all major market players
- The report will provide access to approximately 61 market data tables, 64 figures, and close to 180 pages.
